Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

biosyn arzneimittel gmbh - leber von schaflämmern, fe mit wasser (zur injektion), milz vom lamm, fe mit wasser - injektionslösung - leber von schaflämmern, fe mit wasser (zur injektion) 35.mg; milz vom lamm, fe mit wasser 15.mg

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

shire switzerland gmbh - injektionspräparat

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

shire switzerland gmbh - injektionspräparat

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

ge healthcare buchler gmbh & co.kg - intrinsic factor vom schwein - kapsel - intrinsic factor vom schwein 1.usp-e./nf-e.

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

sano arzneimittelfabrik gmbh - thiaminchloridhydrochlorid, ascorbinsäure, calciumpantothenat, cholinhydrogentartrat (dab), cyanocobalamin, eisen(ii)-sulfat-heptahydrat, folsäure-hydrat, kaliumiodid, riboflavin, nicotinamid, pyridoxinhydrochlorid, rutosid-trihydrat, all-rac-alpha-tocopherolacetat (ph.eur.), zinksulfat-heptahydrat, calciumfluorid, kupfer(ii)-sulfat-pentahydrat, retinol, mangan(ii)-sulfat 4 h<2>o, kaliumsulfat, inositol, intrinsic factor o.w.a., calciumhydrogenphosphat - kapsel - thiaminchloridhydrochlorid 5.mg; ascorbinsäure 50.mg; calciumpantothenat 5.mg; cholinhydrogentartrat (dab) 100.mg; cyanocobalamin 1.µg; eisen(ii)-sulfat-heptahydrat 33.mg; folsäure-hydrat 1.mg; kaliumiodid 6.5mg; riboflavin 500.i.e.; nicotinamid 15.mg; pyridoxinhydrochlorid 0.5mg; rutosid-trihydrat 25.mg; all-rac-alpha-tocopherolacetat (ph.eur.) 1.mg; zinksulfat-heptahydrat 1.38mg; calciumfluorid 0.21mg; kupfer(ii)-sulfat-pentahydrat 2.8mg; retinol 5000.i.e.; mangan(ii)-sulfat 4 h<2>o 3.1mg; kaliumsulfat 11.25mg; inositol 50.mg; intrinsic factor o.w.a. 0.5mg; calciumhydrogenphosphat 493.mg

Europäische Union - Deutsch - EMA (European Medicines Agency)

zoetis belgium sa - synthetic peptide analogue of gnrf conjugated to diptheria toxoid - immunologische tests für suidae - male pigs (from 8 weeks of age); female pigs (from 14 weeks of age) - male pigs:induction of antibodies against gnrf to produce a temporary immunological suppression of testicular function. for use as an alternative to physical castration for the reduction of boar taint caused by the key boar taint compound androstenone, in entire male pigs following the onset of puberty. ein weiterer wichtiger faktor für ebergeruch, skatol, kann ebenfalls als indirekter effekt reduziert werden. aggressives und sexuelles (besteigungs-) verhalten wird ebenfalls reduziert. female pigs:induction of antibodies against gnrf to produce a temporary immunological suppression of ovarian function (suppression of oestrus) in order to reduce the incidence of unwanted pregnancies in gilts intended for slaughter, and to reduce the associated sexual behaviour (standing oestrus).

Europäische Union - Deutsch - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastische mittel - vegzelma in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. vegzelma in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. weitere informationen zum status des humanen epidermalen wachstumsfaktor-rezeptors 2 (her2) finden sie in abschnitt 5. vegzelma in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with vegzelma in combination with capecitabine. weitere informationen zum her2-status finden sie in abschnitt 5. vegzelma, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer (nsclc) other than predominantly squamous cell histology. vegzelma, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent nsclc with epidermal growth factor receptor (egfr) activating mutations (see section 5. vegzelma, in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. vegzelma, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. vegzelma, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (vegf) inhibitors or vegf receptor–targeted agents. vegzelma in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. vegzelma, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Schweiz - Deutsch - Tierarzneimittel Kompendium der Schweiz (Institut für Veterinärpharmakologie und toxikologie)

zoetis schweiz gmbh - bovine rotavirus (lincoln strain), live-attenuated, bovine coronavirus (hansen strain), live-attenuated, escherichia coli (strain nadc 1471 o101), k99 adhesion factor, inactivated - lyophilisat und suspension zur herstellung einer injektionssuspension für rinder - praeparatio cryodesiccata: bovine rotavirus (lincoln strain), live-attenuated 10^7.0 - 10^8.0 u., bovine coronavirus (hansen strain), live-attenuated 10^5.0 - 10^7.5 u., pro vitro, residui: neomycinum. suspension: escherichia coli (strain nadc 1471 o101), k99 adhesion factor, inactivated mind. 4.5 log2 u., aluminii oxidum hydricum max. 7.92 mg, thiomersalum max. 0.20 mg, formaldehydi solutio (35 per centum), dinatrii phosphas, natrii dihydrogenophosphas, natrii chloridum, ad suspensionem pro 2 ml. - attenuierter lebendimpfstoff gegen bovines rota- und coronavirus bei rindern - impfstoffe

Schweiz - Deutsch - Tierarzneimittel Kompendium der Schweiz (Institut für Veterinärpharmakologie und toxikologie)

zoetis schweiz gmbh - gonadotropin-releasing factor (gnrf) analogue conjugated to a carrier protein - injektionslösung für männliche schweine - gonadotropin-releasing factor (gnrf) analogue conjugated to a carrier protein mind. 300 µg, diethylamino-ethylis-dextranum 300 mg, chlorocresolum 2 mg, ureum, aqua ad iniectabile, ad solutionem pro dosi 2 ml. - impfstoff gegen gonadoropin-releasing-faktor (gnrf) bei schweinen - impfstoffe

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - octocogum alfa - lyophilisat und lösungsmittel zur intravenösen injektion - praeparatio cryodesiccata: octocogum alfa 250 u.i., trehalosum dihydricum, histidinum, trometamolum, natrii chloridum, calcii chloridum dihydricum, polysorbatum 80, mannitolum, antiox.: glutathionum 0.4 mg, pro vitro. solvens: aqua ad iniectabile 5 ml. - hämophilie a - biotechnologika